Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Diabetic Microvascular Plasma/Tissue Lipidomics- Comparison (Study ST000667)

C18 NEGATIVE ION MODE (Analysis AN001020)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8
PG 44:11; [M-H]-@4.77	ME182049	1.53	0.31	1.57	0.24	3.97	0.30	1.81	0.27
PG 44:12; [M-H]-@4.52	ME182050	1.94	0.21	1.29	0.25	5.68	0.19	1.61	0.20
PS 36:4; [M-H]-@5.36	ME182070	3.38	0.31	0.86	0.60	2.63	0.41	0.95	0.48
PS 36:5; [M-H]-@4.99	ME182071	3.64	0.82	0.63	0.40	3.46	0.80	0.66	0.35
PG 40:8; [M-H]-@4.68	ME182047	2.07	0.95	0.88	0.87	4.31	0.95	0.53	0.45
CL 74:9; [M-2H](2-)@5.75	ME181831	2.44	1.30	0.48	0.56	3.70	1.11	0.65	0.54
PE 36:5; [M-H]-@5.94	ME181985	2.40	1.35	0.54	0.52	3.81	1.10	0.65	0.50
PG 40:7; [M-H]-@5.10	ME182046	1.34	0.40	1.16	0.85	3.58	0.80	0.97	0.85
PS 38:6; [M-H]-@5.25	ME182077	2.46	0.47	0.98	0.79	3.08	0.16	0.95	0.58
CL 78:13; [M-2H](2-)@5.75	ME181838	2.72	0.57	0.54	0.84	3.31	0.79	0.74	0.68
PE 38:7; [M-H]-@5.67	ME181998	2.37	0.46	0.67	1.06	3.15	0.66	0.74	0.72
CL 74:11; [M-2H](2-)@5.55	ME181825	1.99	0.74	0.94	0.57	2.60	0.84	1.42	0.39
PE 36:6; [M-H]-@5.51	ME181986	1.97	0.50	1.20	0.57	2.96	0.11	1.48	0.39
CL 74:7; [M-2H](2-)@6.03	ME181829	1.97	0.84	0.52	1.71	1.58	0.41	0.53	0.68
PE 36:4; [M-H]-@6.24	ME181984	2.04	0.94	0.53	1.57	1.64	0.45	0.57	0.65
CL 80:13; [M-2H](2-)@6.11	ME181841	1.21	0.40	1.05	1.49	1.32	0.74	1.01	0.80
PE 39:7; [M-H]-@6.09	ME182001	1.05	0.37	0.90	1.90	1.22	0.40	0.88	0.85
CL 76:7; [M-2H](2-)@6.75	ME181836	2.14	1.89	0.32	0.81	2.19	0.64	0.48	0.69
CL 80:7; [M-2H](2-)@7.02	ME181842	1.84	1.47	0.80	0.76	2.53	1.56	0.60	0.50
PE 37:4; [M-H]-@6.70	ME181988	1.87	1.81	0.43	0.84	2.10	1.64	0.52	0.58
PG 42:9; [M-H]-@4.91	ME182048	0.68	1.15	1.66	0.53	2.29	1.27	1.07	0.63
CL 76:12; [M-2H](2-)@8.88	ME181835	1.19	1.33	0.69	0.46	1.01	1.43	1.27	1.06
CL 78:4; [M-2H](2-)@7.02	ME181839	1.38	1.05	1.10	0.81	1.47	0.49	1.33	0.53
PE 38:3; [M-H]-@7.28	ME181992	1.57	1.22	1.16	0.54	1.42	0.49	1.38	0.45
CL 78:5; [M-2H](2-)@7.26	ME181840	1.73	1.29	1.12	0.51	1.50	0.67	1.30	0.39
PE 38:5; [M-H]-@6.51	ME181996	1.91	1.26	1.08	0.47	1.53	0.52	1.26	0.44
PE 38:4; [M-H]-@6.95	ME181994	2.45	1.13	1.08	0.34	2.09	0.40	1.22	0.31
PG 34:2; [M-H]-@5.47	ME182036	1.91	1.35	1.48	0.29	1.88	0.32	1.19	0.27
PG 36:1; [M-H]-@6.46	ME182038	0.13	0.29	0.72	2.24	0.25	0.16	1.10	1.30
PS 40:7; [M-H]-@5.37	ME182085	0.20	0.08	1.09	2.39	0.21	0.05	1.01	1.09
CL 82:5; [M-2H](2-)@7.64	ME181845	0.43	0.55	1.22	1.08	0.24	0.34	1.84	0.90
PE 40:3; [M-H]-@7.63	ME182004	0.35	0.61	1.52	1.05	0.34	0.37	1.58	0.92
plasmenyl-PE 38:5; [M-H]-@6.79	ME182124	0.41	0.67	1.31	1.16	0.42	0.57	1.42	0.99
PE 42:7; [M-H]-@6.99	ME182022	0.19	0.83	1.13	1.57	0.27	0.44	1.24	0.97
PG 36:0; [M-H]-@6.90	ME182037	0.16	1.17	1.09	1.24	0.22	0.77	1.44	0.82
plasmenyl-PE 40:5; [M-H]-@7.34	ME182130	0.21	0.85	1.20	1.28	0.24	0.68	1.56	0.80
CL 86:13; [M-2H](2-)@7.00	ME181846	0.15	0.50	1.75	1.29	0.01	0.16	1.71	0.67
PI 36:1; [M-H]-@6.33	ME182053	0.03	0.35	1.32	1.80	0.00	0.61	1.38	0.94
PG 38:6; [M-H]-@5.36	ME182044	0.31	0.26	1.43	1.58	0.54	0.15	1.44	0.90
PE 41:6; [M-H]-@6.88	ME182014	0.10	0.50	1.13	1.59	0.29	0.10	1.56	1.01
PS 42:6; [M-H]-@6.09	ME182091	0.13	0.25	1.21	1.92	0.02	0.04	1.40	1.02
PE 40:8; [M-H]-@5.95	ME182011	0.87	0.11	0.91	1.85	0.70	0.05	0.97	1.30
PG 32:0; [M-H]-@5.78	ME182033	0.31	0.90	0.88	1.48	0.98	0.61	1.29	0.90
PE 34:4; [M-H]-@5.73	ME181972	0.59	0.81	0.61	1.43	0.77	0.70	0.96	1.43
PE 40:6; [M-H]-@6.04	ME182008	0.81	0.64	0.85	1.56	0.56	0.75	0.84	1.25
PC 31:0; [M-Ac-H]-@6.27	ME181886	0.48	0.39	1.05	1.58	0.40	0.62	1.20	1.17
PS 35:1; [M-H]-@6.12	ME182066	0.56	0.47	0.93	1.69	0.54	0.42	1.10	1.16
PE 38:4; [M-H]-@5.69	ME181995	0.19	0.74	0.83	1.59	0.50	0.33	1.26	1.22
PG 40:6; [M-H]-@5.99	ME182045	0.40	0.44	0.76	1.73	0.54	0.20	1.29	1.23
PC 30:1; [M-Ac-H]-@5.41	ME181885	0.24	0.56	1.57	1.39	0.29	0.80	0.50	1.66
PC 29:0; [M-Ac-H]-@5.59	ME181883	0.32	0.75	1.14	1.18	0.40	1.36	1.27	1.09
PE 36:0; [M-H]-@7.84	ME181977	0.11	0.66	0.85	1.57	0.10	1.03	1.08	1.46
PS 40:4; [M-H]-@6.40	ME182082	0.12	0.64	1.58	0.81	0.03	1.35	2.06	0.61
PS 40:8; [M-H]-@4.90	ME182086	0.18	0.46	1.14	1.20	0.13	1.50	2.20	0.50
PE 42:6; [M-H]-@7.48	ME182021	0.18	0.54	1.67	0.76	0.21	0.72	2.04	0.73
plasmenyl-PE 40:4; [M-H]-@7.66	ME182129	0.11	0.95	1.50	0.73	0.15	0.84	1.80	0.84
plasmenyl-PE 40:4; [M-H]-@7.87	ME182128	0.11	0.95	1.50	0.73	0.15	0.84	1.80	0.84
PE 39:6; [M-H]-@6.64	ME182000	0.37	0.85	1.35	0.88	0.55	1.15	1.93	0.47
plasmenyl-PE 38:6; [M-H]-@6.55	ME182125	0.67	0.58	1.53	0.64	0.77	0.76	2.03	0.53
plasmenyl-PE 36:5; [M-H]-@6.32	ME182120	0.89	1.01	1.04	0.97	1.20	0.63	1.51	0.58
IS PS 34:0 ;[M-H]-	ME181866	0.73	1.36	1.39	0.44	0.70	0.97	1.88	0.30
PE 38:6; [M-H]-@6.15	ME181997	1.01	1.08	1.47	0.51	0.59	0.82	1.78	0.39
PG 36:2; [M-H]-@6.00	ME182039	0.82	0.88	1.64	0.58	0.77	0.09	1.98	0.36
PG 36:3; [M-H]-@5.46	ME182040	0.73	0.99	1.39	0.73	0.49	0.41	1.87	0.48
CL 72:6; [M-2H](2-)@9.35	ME181821	2.02	0.30	1.40	0.31	0.78	0.46	2.05	0.43
CL 72:7; [M-2H](2-)@9.17	ME181822	1.70	0.36	1.35	0.36	1.35	0.13	2.27	0.28
PA 40:6; [M-H]-@5.74	ME181878	0.74	0.27	1.33	1.01	0.72	0.09	1.98	0.72
PE 42:10; [M-H]-@5.86	ME182017	0.75	0.21	1.89	1.02	0.67	0.14	1.62	0.67
PS 38:4; [M-H]-@6.03	ME182075	1.02	0.06	1.67	0.85	1.00	0.03	1.71	0.84
CL 82:15; [M-2H](2-)@5.93	ME181843	1.16	0.18	1.20	1.41	0.95	0.10	1.29	0.90
PS 38:5; [M-H]-@5.57	ME182076	0.75	0.12	1.29	1.05	1.03	0.07	1.59	1.16
CL 82:17; [M-2H](2-)@5.59	ME181844	1.52	0.21	2.09	0.69	0.71	0.35	1.58	0.36
PE 40:9; [M-H]-@5.55	ME182012	1.37	0.19	1.82	1.11	0.62	0.12	1.42	0.49
CL 72:8; [M-2H](2-)@8.97	ME181824	1.39	0.45	1.31	0.83	0.88	0.72	1.87	0.35
PE 40:7; [M-H]-@6.35	ME182010	1.21	0.44	1.42	0.93	1.02	0.29	1.56	0.64
PC 24:6; [M-Ac-H]-@1.37	ME181881	0.21	0.75	0.79	0.25	0.73	1.03	3.38	0.25
CL 74:8; [M-2H](2-)@9.21	ME181830	1.12	0.58	1.66	0.21	0.69	0.46	2.55	0.14
CL 72:5; [M-2H](2-)@9.52	ME181820	0.55	0.59	1.69	0.43	0.43	0.28	2.61	0.26
PE 32:0; [M-H]-@6.75	ME181964	0.65	0.70	1.61	0.27	0.71	0.44	2.63	0.23
PS 38:3; [M-H]-@6.37	ME182074	0.39	0.07	1.97	0.87	0.40	0.03	2.15	0.62
PS 40:5; [M-H]-@6.08	ME182083	0.17	0.22	1.82	1.02	0.27	0.02	2.22	0.57
plasmenyl-PE 36:4; [M-H]-@6.67	ME182119	0.72	0.42	2.11	0.36	0.53	0.27	2.27	0.35
PE 42:11; [M-H]-@5.45	ME182018	0.65	0.24	1.95	0.62	0.53	0.02	2.12	0.60
plasmenyl-PE 38:4; [M-H]-@7.24	ME182123	0.68	0.54	1.73	0.68	0.49	0.35	1.95	0.58
PC 32:0; [M-Ac-H]-@6.55	ME181888	0.68	0.36	1.74	0.59	0.67	0.45	2.22	0.47
plasmenyl-PE 40:6; [M-H]-@7.14	ME182131	0.54	0.40	1.81	0.79	0.70	0.34	2.08	0.43
PS 42:10; [M-H]-@4.86	ME182088	0.04	0.47	2.66	0.47	0.03	0.32	2.12	0.42
PC 42:11; [M-Ac-H]-@5.30	ME181943	0.31	0.58	2.40	0.14	0.25	0.78	2.62	0.06
PI 38:6; [M-H]-@5.12	ME182060	0.21	0.47	2.21	0.40	0.16	0.72	2.37	0.39
PI 40:7; [M-H]-@5.29	ME182063	0.03	0.10	2.34	0.06	0.02	0.19	3.48	0.05
PS 44:11; [M-H]-@4.95	ME182092	0.00	0.01	2.26	0.24	0.00	0.04	3.35	0.19
PC 44:12; [M-Ac-H]-@5.57	ME181955	0.09	0.05	2.76	0.03	0.10	0.08	3.19	0.04
PE 44:12; [M-H]-@5.72	ME182029	0.05	0.02	2.67	0.11	0.06	0.02	3.23	0.07
PS 44:12; [M-H]-@4.75	ME182093	0.00	0.34	2.47	0.13	0.00	0.01	3.12	0.10
PC 44:11; [M-Ac-H]-@5.82	ME181954	0.12	0.14	2.54	0.05	0.12	0.25	3.21	0.05
PG 38:4; [M-H]-@6.08	ME182043	0.07	0.19	2.35	0.18	0.12	0.29	3.15	0.12
PE 42:9; [M-H]-@6.09	ME182025	0.23	0.04	2.65	0.37	0.21	0.05	2.66	0.23
PI 34:1; [M-H]-@5.72	ME182051	0.14	0.07	2.22	0.31	0.23	0.09	3.06	0.25
PS 40:6; [M-H]-@5.97	ME182084	0.15	0.02	2.49	0.28	0.24	0.01	2.99	0.18
PE 44:10; [M-H]-@6.36	ME182028	0.15	0.05	1.85	0.73	0.12	0.06	2.80	0.42
PE 42:8; [M-H]-@6.28	ME182023	0.31	0.14	1.89	0.59	0.17	0.11	2.65	0.49
PE 42:8; [M-H]-@6.56	ME182024	0.16	0.15	1.96	0.58	0.14	0.11	2.73	0.46
PE 40:4; [M-H]-@7.41	ME182005	0.45	0.18	2.10	0.45	0.42	0.09	2.56	0.39
PG 34:1; [M-H]-@5.83	ME182035	0.66	0.08	2.22	0.25	0.59	0.03	2.74	0.24
PE 40:5; [M-H]-@6.39	ME182007	0.25	0.49	2.05	0.34	0.42	0.33	2.66	0.28
PE 40:5; [M-H]-@7.10	ME182006	0.32	0.55	1.94	0.43	0.40	0.36	2.52	0.32
PE 40:6; [M-H]-@6.90	ME182009	0.24	0.44	2.13	0.18	0.38	0.21	2.94	0.16
PG 36:4; [M-H]-@5.46	ME182042	0.13	0.45	2.25	0.29	0.24	0.34	2.80	0.16
PE 35:3; [M-H]-@6.22	ME181975	0.47	0.49	0.23	2.23	0.31	1.50	0.25	1.90
PA 34:1; [M-H]-@5.74	ME181867	0.07	0.32	0.10	2.21	0.03	0.92	0.25	2.57
plasmenyl-PE 40:1; [M-H]-@8.64	ME182126	0.05	0.44	0.05	2.20	0.07	1.40	0.11	2.57
PS 40:1; [M-H]-@7.56	ME182079	0.05	1.35	0.07	2.56	0.06	0.22	0.09	1.72
PC 46:1; [M-Ac-H]-@9.61	ME181960	0.19	0.89	0.14	2.28	0.01	0.78	0.17	2.05
lysoPE 18:1; [M-H]-@1.81	ME182098	0.20	0.92	0.05	2.01	0.17	0.67	0.07	2.45
lysoPE 24:0; [M-H]-@5.25	ME182107	0.06	0.83	0.21	2.08	0.03	0.81	0.14	2.34
CL 72:3; [M-2H](2-)@6.43	ME181819	0.19	1.19	0.09	1.96	0.29	0.41	0.09	2.28
PE 35:2; [M-H]-@6.69	ME181974	0.17	1.12	0.08	2.04	0.26	0.25	0.12	2.29
PA 44:1; [M-H]-@8.32	ME181880	0.14	0.77	0.29	2.09	0.11	0.41	0.36	2.12
PE 36:1; [M-H]-@6.69	ME181979	0.25	0.89	0.14	2.16	0.21	0.45	0.21	2.12
PE 36:2; [M-H]-@6.97	ME181980	0.22	0.88	0.17	2.31	0.21	0.33	0.11	2.10
PA 39:0; [M-H]-@6.95	ME181874	0.28	1.32	0.35	1.91	0.15	0.35	0.54	1.54
PC 46:5; [M-Ac-H]-@8.50	ME181962	0.05	1.40	0.22	2.10	0.23	0.45	0.53	1.50
CL 70:1; [M-2H](2-)@5.34	ME181815	0.05	1.21	0.31	1.83	0.08	1.02	0.28	2.03
plasmenyl-PE 40:2; [M-H]-@8.30	ME182127	0.07	1.38	0.17	1.94	0.05	1.09	0.26	1.89
PC 42:4; [M-Ac-H]-@7.83	ME181946	0.11	1.06	0.24	2.24	0.09	1.07	0.32	1.69
FFA(24:0)	ME181858	0.09	0.93	0.45	2.00	0.17	0.83	0.52	1.72
plasmenyl-PE 38:2; [M-H]-@7.84	ME182121	0.15	0.89	0.53	1.96	0.10	0.94	0.49	1.72
CL 74:5; [M-2H](2-)@5.93	ME181827	0.44	0.81	0.13	3.16	0.33	0.11	0.13	1.20
PC 41:2; [M-Ac-H]-@8.16	ME181939	0.03	0.34	0.07	3.40	0.05	0.17	0.08	1.72
PC 43:2; [M-Ac-H]-@8.66	ME181951	0.05	0.77	0.07	2.59	0.11	1.14	0.09	1.98
PE 39:1; [M-H]-@8.20	ME181999	0.11	0.77	0.13	2.63	0.25	0.92	0.14	1.81
CL 76:1; [M-2H](2-)@5.86	ME181833	0.04	0.93	0.16	2.58	0.15	0.64	0.10	1.86
PC 44:5; [M-Ac-H]-@7.94	ME181959	0.12	0.85	0.22	2.57	0.21	0.69	0.13	1.79
PA 38:3; [M-H]-@5.97	ME181873	0.27	0.27	0.13	2.46	0.31	0.78	0.18	2.25
PS 42:2; [M-H]-@7.60	ME182089	0.03	0.43	0.03	2.83	0.02	0.40	0.07	2.24
PC 40:2; [M-Ac-H]-@7.94	ME181929	0.04	0.26	0.05	2.96	0.03	0.43	0.07	2.21
PE 43:1; [M-H]-@9.07	ME182026	0.01	0.20	0.05	2.89	0.01	0.40	0.08	2.34
PC 44:2; [M-Ac-H]-@8.85	ME181956	0.03	0.12	0.08	2.82	0.02	0.73	0.08	2.37
PC 42:3; [M-Ac-H]-@8.00	ME181945	0.05	0.24	0.08	2.93	0.04	0.86	0.07	2.13
PC 44:3; [M-Ac-H]-@8.50	ME181957	0.04	0.29	0.07	2.84	0.19	0.74	0.10	2.16
CL 72:1; [M-2H](2-)@7.12	ME181818	0.06	0.56	0.10	2.82	0.09	0.61	0.16	1.92
PS 42:1; [M-H]-@10.98	ME182087	0.04	0.43	0.17	2.88	0.09	0.40	0.14	1.97
PE 44:2; [M-H]-@8.85	ME182030	0.08	0.62	0.13	2.80	0.07	0.21	0.15	1.95
PE 42:3; [M-H]-@8.07	ME182020	0.14	0.43	0.16	2.69	0.10	0.32	0.31	1.96
PC 38:1; [M-Ac-H]-@7.83	ME181915	0.05	0.61	0.21	2.56	0.06	0.48	0.32	1.94
PS 38:1; [M-H]-@7.06	ME182072	0.07	0.67	0.16	2.59	0.12	0.34	0.24	1.97
plasmenyl-PE 34:2; [M-H]-@6.74	ME182113	0.07	0.59	0.18	2.38	0.08	0.32	0.14	2.35
CL 68:1; [M-2H](2-)@6.56	ME181814	0.08	0.43	0.12	2.51	0.06	0.27	0.16	2.37
PE 33:1; [M-H]-@6.57	ME181967	0.05	0.50	0.11	2.59	0.08	0.29	0.15	2.27
PC 44:4; [M-Ac-H]-@8.38	ME181958	0.12	0.65	0.12	2.46	0.14	0.72	0.08	2.21
PE 33:2; [M-H]-@6.07	ME181968	0.19	0.44	0.26	2.46	0.20	0.47	0.17	2.17
PA 38:2; [M-H]-@6.41	ME181872	0.13	0.47	0.13	2.54	0.10	0.61	0.17	2.20
PE 35:1; [M-H]-@7.13	ME181973	0.06	0.47	0.16	2.67	0.12	0.45	0.17	2.11
PA 36:1; [M-H]-@6.30	ME181869	0.03	0.13	0.12	2.65	0.02	0.19	0.11	2.58
PS 40:2; [M-H]-@7.11	ME182080	0.03	0.26	0.03	2.76	0.03	0.24	0.04	2.50
PS 36:2; [M-H]-@5.93	ME182068	0.12	0.03	0.14	2.82	0.13	0.02	0.12	2.43
plasmenyl-PE 36:1; [M-H]-@7.69	ME182114	0.02	0.11	0.07	2.88	0.02	0.06	0.08	2.46
PC 44:1; [M-Ac-H]-@9.28	ME181953	0.00	0.07	0.08	2.88	0.02	0.06	0.01	2.57
plasmenyl-PE 36:2; [M-H]-@7.32	ME182116	0.02	0.12	0.04	2.86	0.01	0.04	0.02	2.57
PC 40:0; [M-Ac-H]-@8.76	ME181927	0.10	0.16	0.10	3.00	0.12	0.10	0.15	2.14
PE 40:2; [M-H]-@8.00	ME182003	0.03	0.16	0.12	2.88	0.07	0.15	0.10	2.33
PE 42:2; [M-H]-@8.43	ME182019	0.03	0.14	0.04	2.99	0.09	0.12	0.07	2.35
PC 39:1; [M-Ac-H]-@8.12	ME181924	0.02	0.13	0.10	3.02	0.01	0.07	0.07	2.31
PA 38:1; [M-H]-@6.88	ME181871	0.01	0.22	0.08	3.01	0.02	0.04	0.02	2.31
PE 44:1; [M-H]-@9.27	ME182027	0.02	0.22	0.02	2.98	0.02	0.03	0.08	2.32
PC 42:2; [M-Ac-H]-@8.39	ME181944	0.01	0.09	0.01	3.13	0.02	0.21	0.03	2.32
PC 40:1; [M-Ac-H]-@8.29	ME181928	0.01	0.04	0.01	3.17	0.01	0.08	0.02	2.35
PE 42:1; [M-H]-@8.74	ME182016	0.00	0.02	0.01	3.18	0.01	0.04	0.01	2.38
PE 42:1; [M-H]-@8.88	ME182015	0.00	0.02	0.01	3.18	0.01	0.04	0.01	2.38
PC 41:1; [M-Ac-H]-@8.58	ME181938	0.00	0.06	0.05	3.13	0.01	0.05	0.05	2.31
PE 40:1; [M-H]-@8.39	ME182002	0.02	0.10	0.01	3.18	0.02	0.07	0.03	2.27
PC 42:1; [M-Ac-H]-@8.73	ME181941	0.00	0.03	0.01	3.10	0.00	0.03	0.01	2.46
PC 43:1; [M-Ac-H]-@9.06	ME181950	0.05	0.05	0.01	3.08	0.07	0.05	0.04	2.38
PE 41:1; [M-H]-@8.64	ME182013	0.03	0.05	0.10	3.06	0.03	0.08	0.02	2.36
plasmenyl-PE 36:2; [M-H]-@6.13	ME182117	0.02	0.11	0.06	2.29	0.01	0.36	0.07	3.03
plasmenyl-PE 32:1; [M-H]-@6.56	ME182109	0.06	0.30	0.22	2.25	0.07	0.11	0.16	2.70
plasmenyl-PE 34:1; [M-H]-@7.12	ME182112	0.08	0.39	0.11	2.42	0.09	0.10	0.13	2.56
PA 36:2; [M-H]-@5.87	ME181870	0.13	0.27	0.18	2.35	0.14	0.46	0.23	2.47
plasmenyl-PE 36:1; [M-H]-@6.31	ME182115	0.03	0.28	0.11	2.44	0.02	0.38	0.08	2.67
PE 32:1; [M-H]-@6.22	ME181965	0.15	0.26	0.49	2.39	0.24	0.24	0.32	2.11
CL 78:1; [M-2H](2-)@7.71	ME181837	0.11	0.39	0.39	2.49	0.13	0.15	0.52	1.85
PE 38:1; [M-H]-@7.92	ME181990	0.12	0.15	0.48	2.38	0.21	0.09	0.62	1.97
CL 66:1; [M-2H](2-)@6.24	ME181812	0.16	0.10	0.47	2.67	0.27	0.14	0.31	1.99
PS 36:1; [M-H]-@6.40	ME182067	0.18	0.13	0.25	2.72	0.18	0.08	0.27	2.14
plasmenyl-PE 36:3; [M-H]-@6.91	ME182118	0.13	0.31	0.31	2.77	0.10	0.13	0.37	1.84
PS 36:3; [M-H]-@5.58	ME182069	0.34	0.19	0.33	2.86	0.20	0.05	0.34	1.73
CL 70:5; [M-2H](2-)@6.06	ME181816	0.43	0.61	0.29	2.50	0.47	0.27	0.22	1.75
PE 34:3; [M-H]-@6.00	ME181971	0.39	0.64	0.38	2.42	0.44	0.31	0.24	1.74
PS 34:1; [M-H]-@5.94	ME182064	0.46	0.11	0.47	2.45	0.67	0.10	0.37	1.89
PS 34:2; [M-H]-@5.35	ME182065	0.54	0.39	0.60	2.34	0.48	0.01	0.32	1.71
CL 66:3; [M-2H](2-)@5.71	ME181813	0.38	0.24	0.74	2.05	0.33	0.58	0.23	2.12
PE 32:2; [M-H]-@5.73	ME181966	0.30	0.57	0.52	2.05	0.27	0.32	0.22	2.16
PE 37:1; [M-H]-@7.31	ME181987	0.30	0.64	0.55	1.92	0.40	0.11	0.44	2.01
PA 35:1; [M-H]-@6.12	ME181868	0.10	0.40	0.43	2.06	0.04	0.27	0.55	2.19
PC 28:0; [M-Ac-H]-@5.24	ME181882	0.11	0.38	0.86	2.11	0.15	0.40	0.46	1.86
PC 32:1; [M-Ac-H]-@6.07	ME181889	0.11	0.42	0.58	2.21	0.13	0.39	0.56	1.86
PE 36:1; [M-H]-@7.41	ME181978	0.15	0.15	0.66	2.15	0.12	0.05	0.82	1.86
PS 38:2; [M-H]-@6.55	ME182073	0.09	0.16	0.60	2.36	0.08	0.06	0.79	1.76
PC 30:0; [M-Ac-H]-@5.94	ME181884	0.19	0.26	0.84	1.93	0.22	0.30	0.85	1.73
PE 38:2; [M-H]-@7.49	ME181991	0.36	0.26	0.83	1.71	0.39	0.26	1.02	1.65
FFA(22:1)	ME181855	0.84	0.79	0.13	2.15	0.78	0.77	0.16	1.74
CL 72:7; [M-2H](2-)@6.08	ME181823	0.96	1.34	0.47	1.43	1.37	0.45	0.51	1.27
CL 74:3; [M-2H](2-)@6.22	ME181826	0.80	1.46	0.24	1.83	0.66	0.74	0.23	1.42
PE 34:2; [M-H]-@6.39	ME181970	0.59	1.76	0.41	1.66	0.61	1.05	0.25	1.26
PA 39:2; [M-H]-@6.52	ME181875	0.95	1.75	0.40	1.73	0.64	0.33	0.31	1.07
PC 34:4; [M-Ac-H]-@5.54	ME181897	0.99	1.53	0.32	2.03	1.02	0.75	0.08	1.06
PE 35:4; [M-H]-@6.07	ME181976	0.90	1.20	0.47	1.68	0.98	0.68	0.50	1.22
CL 74:5; [M-2H](2-)@6.56	ME181828	1.11	1.09	0.37	1.93	0.94	0.46	0.37	1.18
PE 36:3; [M-H]-@6.53	ME181982	0.95	1.28	0.36	1.90	0.83	0.50	0.32	1.22
plasmenyl-PE 33:1; [M-H]-@6.89	ME182110	0.05	2.94	0.08	1.49	0.03	0.06	0.05	1.58
PC 43:4; [M-Ac-H]-@8.18	ME181952	0.06	2.18	0.06	2.04	0.19	0.39	0.10	1.52
PC 31:1; [M-Ac-H]-@5.77	ME181887	0.24	1.72	0.35	1.68	0.32	0.85	0.26	1.63
PS 40:3; [M-H]-@6.77	ME182081	0.06	2.09	0.25	1.72	0.24	0.89	0.44	1.30
PC 42:5; [M-Ac-H]-@7.45	ME181947	0.19	1.16	0.45	1.78	0.17	2.91	0.88	0.92
PE 36:4; [M-H]-@5.40	ME181983	0.62	0.97	0.78	1.41	0.31	2.65	0.46	1.36
CL 70:7; [M-2H](2-)@5.44	ME181817	0.46	0.70	0.58	1.97	0.64	1.73	0.41	1.45
PE 38:3; [M-H]-@6.31	ME181993	0.46	1.16	0.37	1.79	0.42	2.04	0.44	1.38
PE 44:3; [M-H]-@8.49	ME182031	0.15	1.06	0.24	2.52	0.11	1.62	0.26	1.34
PA 42:1; [M-H]-@8.67	ME181879	0.11	1.06	0.23	2.04	0.16	1.56	0.21	1.91
PC 35:1; [M-Ac-H]-@7.02	ME181899	0.10	1.24	0.40	1.90	0.04	1.57	0.33	1.68
PS 39:1; [M-H]-@7.42	ME182078	0.07	1.53	0.17	2.17	0.00	1.69	0.24	1.45
PC 46:4; [M-Ac-H]-@8.96	ME181961	0.16	1.48	0.24	1.94	0.05	1.67	0.24	1.60
plasmenyl-PE 42:1; [M-H]-@9.04	ME182132	0.16	1.60	0.13	1.99	0.08	1.54	0.16	1.65
PC 32:2; [M-Ac-H]-@5.58	ME181890	0.17	1.57	0.37	1.85	0.20	1.85	0.17	1.51
PC 37:1; [M-Ac-H]-@7.59	ME181911	0.10	1.52	0.37	1.88	0.12	1.80	0.48	1.28
lysoPE 22:4; [M-H]-@1.89	ME182104	0.10	1.35	0.60	1.41	0.15	1.86	0.45	1.72
PE 34:1; [M-H]-@5.47	ME181969	0.11	1.71	0.20	1.52	0.29	1.65	0.19	1.91
PI 34:2; [M-H]-@5.27	ME182052	0.22	2.31	0.58	1.43	0.13	2.00	0.53	0.77
plasmenyl-PE 42:4; [M-H]-@8.09	ME182133	0.10	2.07	0.56	0.99	0.08	2.07	0.83	1.18
FFA(22:0)	ME181854	0.22	2.11	0.51	1.28	0.26	2.02	0.56	1.08
PC 33:1; [M-Ac-H]-@6.43	ME181892	0.11	1.98	0.57	1.28	0.10	1.83	0.59	1.23
PC 33:0; [M-Ac-H]-@6.91	ME181891	0.34	1.22	0.88	1.50	0.21	1.84	0.83	0.98
PC 34:1; [M-Ac-H]-@6.65	ME181894	0.15	1.50	0.60	1.49	0.12	1.38	0.69	1.35
PC 35:0; [M-Ac-H]-@7.50	ME181898	0.07	1.73	0.68	1.45	0.05	1.32	0.79	1.11
lysoPE 16:1; [M-H]-@1.20	ME182096	0.25	2.35	0.06	1.28	0.44	1.71	0.13	1.68
lysoPE 20:1; [M-H]-@2.57	ME182100	0.24	2.66	0.21	1.13	0.23	2.03	0.13	1.44
PE 44:4; [M-H]-@8.55	ME182032	0.84	1.61	0.47	1.12	0.71	1.30	0.69	1.22
FFA(24:2)	ME181860	0.43	2.14	0.24	1.59	0.47	1.55	0.21	1.24
PE 36:2; [M-H]-@6.11	ME181981	0.71	2.02	0.30	1.42	0.72	1.42	0.24	1.23
FFA(22:3)	ME181857	0.21	5.62	0.21	0.19	0.09	1.05	0.24	0.16
PC 40:5; [M-Ac-H]-@7.16	ME181933	0.16	7.25	NA	0.28	NA	NA	0.23	0.12
PC 36:3; [M-Ac-H]-@6.40	ME181907	0.26	4.88	0.20	0.19	0.19	3.98	0.22	0.14
lysoPE 22:5; [M-H]-@1.49	ME182105	0.12	4.92	0.11	0.25	0.12	3.96	0.18	0.25
PC 34:2; [M-Ac-H]-@6.23	ME181895	0.20	4.96	0.13	0.29	0.15	3.78	0.11	0.22
PC 34:3; [M-Ac-H]-@5.76	ME181896	0.15	4.70	0.15	0.35	0.14	4.26	0.13	0.26
PC 35:2; [M-Ac-H]-@6.56	ME181900	0.05	4.95	0.12	0.32	0.08	4.13	0.09	0.27
PC 36:2; [M-Ac-H]-@6.82	ME181906	0.12	5.16	0.14	0.24	0.11	3.34	0.15	0.20
FFA(18:1)	ME181849	0.07	5.32	0.07	0.21	0.06	3.82	0.08	0.18
lysoPE 20:3; [M-H]-@1.58	ME182101	0.13	5.46	0.04	0.09	0.12	3.57	0.13	0.15
FFA(18:2)	ME181850	0.08	5.38	0.02	0.15	0.06	4.54	0.03	0.13
lysoPE 22:6; [M-H]-@1.28	ME182106	0.15	4.80	0.19	0.07	0.21	4.70	0.39	0.07
lysoPE 20:5; [M-H]-@1.07	ME182103	0.17	5.34	0.06	0.03	0.32	5.11	0.04	0.03
PC 36:5; [M-Ac-H]-@5.69	ME181909	0.26	4.94	0.11	0.11	0.38	4.98	0.11	0.11
lysoPE 20:4; [M-H]-@1.35	ME182102	0.24	5.65	0.08	0.06	0.26	3.02	0.09	0.06
FFA(20:1)	ME181852	0.09	5.72	0.07	0.13	0.05	2.92	0.06	0.12
lysoPE 18:2; [M-H]-@1.37	ME182099	0.08	5.85	0.01	0.14	0.07	2.91	0.02	0.12
FFA(20:2)	ME181853	0.16	5.68	0.12	0.14	0.09	2.33	0.15	0.10
PC 37:4; [M-Ac-H]-@6.56	ME181912	0.16	5.41	0.13	0.16	0.25	2.30	0.18	0.22
PC 38:4; [M-Ac-H]-@6.83	ME181918	0.31	4.72	0.37	0.14	0.29	2.69	0.46	0.14
PC 35:4; [M-Ac-H]-@5.93	ME181902	0.30	4.55	0.30	0.42	0.26	2.38	0.30	0.30
PC 36:4; [M-Ac-H]-@6.10	ME181908	0.45	4.62	0.33	0.30	0.37	2.19	0.35	0.22
PC 38:5; [M-Ac-H]-@6.39	ME181920	0.43	4.37	0.34	0.19	0.27	3.31	0.52	0.16
PC 35:3; [M-Ac-H]-@6.10	ME181901	0.16	4.62	0.16	0.49	0.15	3.18	0.26	0.27
PC 38:3; [M-Ac-H]-@7.09	ME181917	0.11	4.76	0.18	0.42	0.12	3.08	0.19	0.33
PE 30:0; [M-H]-@6.08	ME181963	0.16	0.51	1.45	0.74	0.29	2.65	1.81	0.79
CL 74:9; [M-2H](2-)@9.16	ME181832	0.96	1.17	1.67	0.24	1.00	2.17	1.67	0.22
CL 76:11; [M-2H](2-)@9.09	ME181834	0.96	1.19	1.38	0.32	1.28	2.90	1.64	0.17
plasmenyl-PE 32:0; [M-H]-@7.09	ME182108	0.22	2.46	0.88	0.51	0.24	0.50	1.30	0.84
plasmenyl-PE 34:0; [M-H]-@7.53	ME182111	0.16	1.84	0.91	0.90	0.16	0.16	1.32	1.01
PC 36:0; [M-Ac-H]-@7.78	ME181903	0.13	1.41	1.65	1.00	0.28	1.54	1.18	0.53
PC 36:1; [M-Ac-H]-@7.26	ME181905	0.12	1.82	0.95	1.06	0.09	1.12	1.19	0.81
plasmenyl-PE 38:3; [M-H]-@7.53	ME182122	0.44	1.55	1.33	0.82	0.34	0.97	1.26	0.69
PC 42:10; [M-Ac-H]-@5.72	ME181942	0.74	2.54	1.03	0.24	0.41	1.81	1.38	0.23
PC 40:5; [M-Ac-H]-@6.87	ME181932	0.22	2.99	1.14	0.14	0.20	1.51	1.58	0.09
PC 40:7; [M-Ac-H]-@6.23	ME181935	0.38	2.62	1.09	0.32	0.34	2.49	1.30	0.22
PC 40:6; [M-Ac-H]-@6.70	ME181934	0.16	2.68	1.34	0.09	0.24	2.12	1.65	0.07
PC 40:9; [M-Ac-H]-@5.42	ME181937	0.12	3.02	1.06	0.29	0.09	1.91	1.32	0.25
PI 38:4; [M-H]-@5.89	ME182058	0.13	2.88	1.01	0.31	0.09	2.17	1.36	0.28
PI 40:6; [M-H]-@5.82	ME182062	0.28	1.13	1.60	0.40	0.44	1.82	2.08	0.32
PS 46:10; [M-H]-@5.85	ME182094	0.33	1.26	1.64	0.38	0.58	1.57	1.86	0.41
PI 36:4; [M-H]-@5.26	ME182056	0.10	1.68	1.65	0.15	0.06	1.94	2.16	0.17
PC 36:6; [M-Ac-H]-@5.44	ME181910	0.29	1.84	1.58	0.22	0.34	1.85	1.87	0.16
PI 38:5; [M-H]-@5.42	ME182059	0.13	1.90	1.45	0.27	0.07	1.68	1.99	0.23
IS PC 34:0;[M-Ac-H]-	ME181862	0.18	1.91	1.52	0.30	0.21	2.35	1.71	0.22
plasmenyl-PE 42:6; [M-H]-@7.76	ME182135	0.16	1.95	1.23	0.52	0.27	2.01	1.56	0.43
PC 36:1; [M-Ac-H]-@5.86	ME181904	0.08	2.57	0.46	0.68	0.03	4.87	0.89	0.57
PC 41:6; [M-Ac-H]-@7.09	ME181940	0.11	1.56	0.62	1.06	0.19	4.48	1.07	0.73
PC 42:6; [M-Ac-H]-@7.30	ME181948	0.18	1.22	0.99	1.07	0.09	3.80	1.27	0.61
FFA(24:3)	ME181861	0.62	2.06	0.20	1.35	0.54	3.67	0.34	0.89
PC 40:3; [M-Ac-H]-@7.52	ME181930	0.22	2.32	0.19	1.28	0.18	3.81	0.42	0.96
FFA(24:1)	ME181859	0.29	2.50	0.15	1.35	0.26	2.65	0.11	1.27
PI 36:2; [M-H]-@5.91	ME182054	0.17	2.91	0.17	1.18	0.12	3.29	0.22	0.95
PC 33:2; [M-Ac-H]-@5.96	ME181893	0.12	4.19	0.18	0.75	0.11	3.82	0.18	0.32
PC 38:2; [M-Ac-H]-@7.41	ME181916	0.21	3.32	0.39	0.66	0.16	4.07	0.46	0.53
PC 38:8; [M-Ac-H]-@5.04	ME181923	0.36	3.51	0.43	0.44	0.21	4.13	0.68	0.24
PC 40:8; [M-Ac-H]-@5.78	ME181936	0.95	3.21	0.40	0.56	0.76	2.10	0.55	0.47
lysoPE 18:0; [M-H]-@2.46	ME182097	0.84	3.74	0.25	0.33	1.39	2.76	0.42	0.32
FFA(22:2)	ME181856	0.56	3.40	0.36	0.77	0.28	2.89	0.29	0.56
PC 38:7; [M-Ac-H]-@5.53	ME181922	0.56	3.40	0.22	0.93	0.52	3.19	0.21	0.49
lysoPE 16:0; [M-H]-@1.67	ME182095	0.56	3.85	0.10	0.56	0.71	2.84	0.21	0.62
PC 37:5; [M-Ac-H]-@6.05	ME181913	0.49	3.62	0.34	0.54	0.81	3.18	0.39	0.42
IS PE 34:0 ;[M-H]-	ME181863	0.15	3.83	0.76	0.12	0.16	3.19	0.94	0.11
PC 39:6; [M-Ac-H]-@6.45	ME181925	0.42	2.84	0.68	0.55	0.36	3.46	0.84	0.38
PC 38:6; [M-Ac-H]-@6.04	ME181921	0.70	2.96	0.69	0.35	0.86	3.08	0.85	0.27
PS 42:5; [M-H]-@6.41	ME182090	0.70	2.96	0.69	0.35	0.86	3.08	0.85	0.27
PC 39:7; [M-Ac-H]-@6.02	ME181926	0.39	2.84	0.56	0.76	0.53	2.69	0.55	0.70
FFA(20:0)	ME181851	0.22	3.60	0.56	0.42	0.17	3.45	0.69	0.30
FFA(16:0)	ME181847	0.17	3.21	0.62	0.56	0.17	3.20	0.80	0.39
PC 37:6; [M-Ac-H]-@5.80	ME181914	0.24	3.37	0.49	0.59	0.25	3.01	0.69	0.44
Arachidonic acid	ME181811	0.41	3.43	0.62	0.39	0.36	2.52	0.80	0.34
PC 40:4; [M-Ac-H]-@7.31	ME181931	0.19	2.91	0.72	0.68	0.16	2.85	0.72	0.58
FFA(18:0)	ME181848	0.17	3.23	0.68	0.52	0.17	2.76	0.90	0.36
PI 38:3; [M-H]-@6.13	ME182057	0.10	3.10	0.69	0.55	0.09	2.56	0.91	0.51
PC 38:5; [M-Ac-H]-@5.71	ME181919	0.24	2.80	0.55	0.23	0.72	3.90	1.37	0.24
PA 40:4; [M-H]-@6.47	ME181876	0.10	2.11	1.05	0.45	0.11	4.13	1.30	0.41
PA 40:5; [M-H]-@5.94	ME181877	0.09	2.24	0.99	0.37	0.06	3.54	1.70	0.16
PC 42:9; [M-Ac-H]-@5.98	ME181949	0.49	2.31	0.84	0.40	0.27	3.38	1.47	0.19
IS PG 34:0 ;[M-H]-	ME181864	0.05	2.80	1.11	0.20	0.07	3.55	1.41	0.11
IS PI 37:4 ;[M-H]-	ME181865	0.04	2.96	0.92	0.23	0.04	3.05	1.43	0.20
PI 36:3; [M-H]-@5.42	ME182055	0.14	2.58	0.98	0.34	0.06	2.97	1.39	0.33
PE 37:5; [M-H]-@6.13	ME181989	0.69	1.86	0.79	0.89	0.71	2.50	1.00	0.53
PG 36:4; [M-H]-@4.79	ME182041	0.93	2.08	0.47	1.20	0.73	2.52	0.56	0.60
PG 33:0; [M-H]-@6.09	ME182034	0.10	1.89	0.92	0.97	0.29	3.10	0.96	0.67
PI 40:5; [M-H]-@6.00	ME182061	0.31	2.38	0.84	0.70	0.40	2.68	1.09	0.43
plasmenyl-PE 42:5; [M-H]-@7.85	ME182134	0.08	2.38	0.82	0.70	0.12	2.76	0.92	0.80

Factors:

F1	CONTROL_DIABETIC:db/db diabetic \| Sample type:Kidney
F2	CONTROL_DIABETIC:db/db diabetic \| Sample type:Plasma
F3	CONTROL_DIABETIC:db/db diabetic \| Sample type:Retina
F4	CONTROL_DIABETIC:db/db diabetic \| Sample type:Sciatic Nerve
F5	CONTROL_DIABETIC:db/m control \| Sample type:Kidney
F6	CONTROL_DIABETIC:db/m control \| Sample type:Plasma
F7	CONTROL_DIABETIC:db/m control \| Sample type:Retina
F8	CONTROL_DIABETIC:db/m control \| Sample type:Sciatic Nerve

Data matrix